Explore All Access
Check if your research matches the topics covered in BioDrugs?
- Degree of match
- Common matching concepts
- Additional journal recommendations
BioDrugs : Impact Factor & More
eISSN: 1179-190XpISSN: 1173-8804
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Aims and Scope
BioDrugs is a peer-reviewed pharmacology journal. BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. It has a 2020 impact factor of 5.807. It is published by Adis International (SpringerNature). Less
BioDrugs Key Metrics
CiteScore 
10.5
Eigenfactor
0.001 - 0.005
H-Index
76
Impact Factor
5 - 10
SJR
Q1Pharmacology
SNIP
1.74
Topics Covered on BioDrugs
Cancer
Bevacizumab
Infliximab
Synthetic drugs
Adalimumab
Clinical trial
Immunotherapy
Systematic review
Breast cancer
Rituximab
Objective response
Chimeric antigen receptor
Multiple sclerosis
Confidence interval
Biosimilar
Antibody-drug conjugate
Filgrastim
Etanercept
Epoetin alpha
Trastuzumab
BioDrugs Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | ADIS INT LTD |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1994 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in BioDrugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in BioDrugs
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins.
- 25 Oct 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review.
- 17 Oct 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness.
- 16 Oct 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy.
- 15 Oct 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis.
- 15 Oct 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
- 30 Sep 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins.
- 25 Oct 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review.
- 17 Oct 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness.
- 16 Oct 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy.
- 15 Oct 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis.
- 15 Oct 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
- 30 Sep 2024
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Compare Similar Journals with BioDrugs
Select Journals to Compare with BioDrugs
Total journals - 10
You can select up to 3 Journals at a time
Annals of the Rheumatic Diseases
Publisher: BMJ PUBLISHING GROUP
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Annals of Oncology
Publisher: ELSEVIER
Expert Opinion on Biological Therapy
Publisher: TAYLOR & FRANCIS LTD
Frontiers in Pharmacology
Publisher: FRONTIERS MEDIA SA
PLoS ONE
Publisher: PUBLIC LIBRARY SCIENCE
Medicine
Publisher: Elsevier
Rheumatology
Publisher: OXFORD UNIV PRESS
Scientific Reports
Publisher: NATURE PORTFOLIO
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
0 Journals Selected to compare with
BioDrugs
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on BioDrugs
How long has BioDrugs been actively publishing? 
BioDrugs has been in operation since 1994 till date.
What is the publishing frequency of BioDrugs?
BioDrugs published with a Bi-monthly frequency.
How many articles did BioDrugs publish last year?
In 2023, BioDrugs publsihed 66 articles.
What is the eISSN & pISSN for BioDrugs?
For BioDrugs, eISSN is 1179-190X and pISSN is 1173-8804.
What is Citescore for BioDrugs?
Citescore for BioDrugs is 10.5.
What is the H Index for BioDrugs ?
H Index for BioDrugs is 76.
What is SNIP score for BioDrugs?
SNIP score for BioDrugs is 1.74.
What is the SJR for BioDrugs?
SJR for BioDrugs is Q1.
Who is the publisher of BioDrugs?
ADIS INT LTD is the publisher of BioDrugs.
